Stockscreener 앱 받기
4.35
11.25%
0.44
전일 마감가:
$3.91
열려 있는:
$3.98
하루 거래량:
668.53K
Relative Volume:
1.12
시가총액:
$167.70M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-1.6353
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
+20.17%
1개월 성능:
+41.23%
6개월 성능:
-40.82%
1년 성능:
-80.73%
1일 변동 폭
$3.965
$4.36
1주일 범위
$3.55
$4.36
52주 변동 폭
$2.235
$28.93
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.35 | 167.70M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
ProShare Advisors LLC Increases Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Bank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Two Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Tesco (LON:TSCO) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Telsey Advisory Group Forecasts Macy’s’ Q2 Earnings (NYSE:M) - Defense World
D. E. Shaw & Co. Inc. Purchases 12,217 Shares of Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World
4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus
4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com
Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance
Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World
HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com
Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World
Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Contrasting Genfit (NASDAQ:GNFT) & 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Sto - GuruFocus
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Barclays PLC - The AM Reporter
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Stock News - GuruFocus
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Price Target from Brokerages - Defense World
4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks
4D Molecular Therapeutics Inc Reports Q1 2025 EPS of -$0.86, Missing Estimates; Revenue Falls Short at $14,000 - GuruFocus
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trials for 4D-150 in Wet AMD, Receives FDA RMAT Designation for DME - Nasdaq
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - Yahoo Finance
Raymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide - GlobeNewswire Inc.
Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World
4D Molecular Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Are 4D Molecular Therapeutics Inc’shares a good deal? - uspostnews.com
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):